Business
Lobe Sciences Reports First Quarter 2026 Results and Highlights
VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited ...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter.","length":423,"tagName":"p"},{"type":"text","content":""During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D expenditures increasing to just under $1 million as we advanced our core programs through Cynaptec Pharmaceuticals, Inc.," said Dr. Fred Sancilio, CEO of Lobe Sciences Ltd. "This progress reflects our transformative approach to drug development of next-generation serotonergic agents, combining our advanced pharmaceutical development expertise, focused subsidiary-level execution with centralized scientific and regulatory core competencies. Importantly, this increased level of activity was achieved alongside improved operating efficiency, underscoring the benefits of our shared services model. We believe this disciplined and scalable approach positions the Company to continue advancing development initiatives while maintaining a strong financial foundation".","length":912,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash totaled $5,991,614 as of November 30, 2025.","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Short-term investments totaled $1,025,098 as of November 30, 2025.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Net working capital totaled $4,047,891 as of November 30, 2025.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Research and development expenses totaled $982,087 for the quarter ended November 30, 2025, compared to $7,551 for the same period in the prior year. The increase reflects expenditures related to advancing L-130 (Psilocin Mucate) through preclinical studies and regulatory activities supporting proof-of-concept and investigational new drug filings.","length":349,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash flows...